Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
0.00
+0.4310 (1.37%)
Apr 14, 2026, 9:44 AM EDT - Market open
Immunocore Holdings Revenue
In the year 2025, Immunocore Holdings had annual revenue of $400.02M with 28.95% growth. Immunocore Holdings had revenue of $104.48M in the quarter ending December 31, 2025, with 24.30% growth.
Revenue (ttm)
$400.02M
Revenue Growth
+28.95%
P/S Ratio
3.99
Revenue / Employee
$763,389
Employees
524
Market Cap
1.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.02M | 89.81M | 28.95% |
| Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
| Dec 31, 2023 | 249.43M | 75.07M | 43.05% |
| Dec 31, 2022 | 174.36M | 137.88M | 377.91% |
| Dec 31, 2021 | 36.48M | -4.69M | -11.39% |
| Dec 31, 2020 | 41.17M | 7.13M | 20.95% |
| Dec 31, 2019 | 34.04M | 3.91M | 12.98% |
| Dec 31, 2018 | 30.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 868.45M |
| Ardelyx | 407.32M |
| Iovance Biotherapeutics | 263.50M |
| Nurix Therapeutics | 71.78M |
| Viridian Therapeutics | 70.85M |
| Vir Biotechnology | 68.56M |
| Intellia Therapeutics | 67.67M |
| Nuvation Bio | 62.90M |
IMCR News
- 8 days ago - Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 27 days ago - Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting - GlobeNewsWire
- 6 weeks ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 6 weeks ago - Immunocore reports fourth quarter and full year 2025 financial results and provides a business update - GlobeNewsWire
- 7 weeks ago - Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 - GlobeNewsWire
- 2 months ago - Immunocore announces R&D leadership evolution - GlobeNewsWire
- 3 months ago - Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 months ago - Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting - GlobeNewsWire